(n=6) remain disease-free more than two years after treatment 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive ...
Long-term PEACE-1 trial results show that adding abiraterone to ADT and docetaxel reduced the risk of death by 32 percent in ...
In the first-in-human TheraPb phase 1 trial, the alpha-emitting radiopharmaceutical 212Pb-ADVC001 was well tolerated at doses ...
MedPage Today on MSN
Lower metastasis risk in very high-risk prostate cancer with intensified treatment
Adding darolutamide to ADT and RT improved metastasis-free survival, but questions persist ...
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...
Pharmaceutical Technology on MSN
Pfizer’s prostate cancer combo moves to earlier line on expanded US approval
Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific ...
Yesterday, the United States Food and Drug Administration (FDA) announced the approval of a new immune-based approach for ...
Darolutamide improved metastasis-free survival alongside hormone therapy and radiotherapy in very high-risk prostate cancer.
DASL-HiCaP Trial Shows Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer / DASL-HiCaP Trial, ...
New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results